Search

A case series of six patients is described in this article, all of whom developed various bleeding complications while receiving heparin or bivalirudin for thrombosis prophylaxis. The patients had a medical history of acute respiratory distress syndrome (ARDS) secondary to COVID-19 and were scheduled for lung transplants. Bleeding events included oozing from central venous catheters, bleeding from the femoral site, epistaxis, and bleeding from various other sites. Some patients also experienced lack of efficacy with bivalirudin. The article provides detailed information about each patient's treatment and outcomes. [Extracted from the article]

A 6-year-old boy with juvenile idiopathic arthritis (JIA) exhibited a lack of efficacy during treatment for anti-melanoma differentiation-associated gene-5 rapidly progressive interstitial lung disease (MDA-5 RP-ILD). He had faltering growth, chronic cough, and was initially treated with prednisolone and methotrexate. However, his condition worsened, requiring invasive mechanical ventilation and additional treatments including methylprednisolone, tacrolimus, cyclophosphamide, tofacitinib, plasmapheresis, and immune-globulin. Despite these interventions, the boy's respiratory failure did not improve, and his family ultimately decided to shift to comfort care. [Extracted from the article]

A 27-year-old man with a history of IV drug use was treated for acute infective endocarditis (IE) of a tricuspid valve with gentamicin and vancomycin. Despite aggressive antibiotic treatment, the patient's condition worsened, and he developed acute respiratory failure, shock, and encephalopathy. He ultimately suffered a cardiac arrest and died. Autopsy results confirmed the diagnosis of acute IE and purulent pneumonia caused by Serratia marcescens. The cause of death was determined to be bilateral purulent pneumonia, acute IE, and acute respiratory distress syndrome (ARDS). [Extracted from the article]

In a case series involving 5 patients, a 61-year-old man with severe acute respiratory failure due to COVID-19 was treated with enoxaparin-sodium for pulmonary embolism. Despite receiving the medication, the man experienced severe gas exchange impairment and developed a stroke due to middle cerebral artery thrombosis. This suggests that enoxaparin-sodium was not effective in preventing the stroke. The patient was subsequently treated with antiplatelet therapy and eventually discharged from the hospital after his COVID-19 improved. [Extracted from the article]

A 37-year-old woman presented with a high fever and headache lasting 10 days, along with dyspnea, tachycardia, and tachypnea. She was diagnosed with scrub typhus, acute respiratory distress syndrome (ARDS), sepsis, and multiorgan dysfunction syndrome. Despite receiving treatment with meropenem, doxycycline, artesunate, tigecycline, and caspofungin, she died from refractory cardiopulmonary arrest. The ultimate diagnosis was scrub typhus-induced severe ARDS with severe sepsis and septic shock. [Extracted from the article]

A 23-year-old woman with adult-onset Still's disease experienced a lack of efficacy with multiple drugs used for her treatment. She had been receiving methotrexate, anakinra, tocilizumab, and canakinumab for her condition, as well as prednisolone for adult-onset Still's disease and macrophage activation syndrome-haemophagocytic lymphohistiocytosis (MAS-HLH). She also received antimicrobial treatment and immunosuppressant drug therapy. Despite these interventions, her condition worsened, leading to her death. [Extracted from the article]

A case report published in Reactions Weekly describes the lack of efficacy of ganciclovir and valganciclovir in treating a 2-month-old girl with Cytomegalovirus (CMV) infection. The girl, who had a history of aseptic meningitis, was hospitalized with symptoms including fever, nasal congestion, reduced feeding, and yellow eye discharge. Despite receiving treatment with ganciclovir and later valganciclovir, her condition worsened and she ultimately died from acute respiratory distress syndrome caused by CMV infection. The report highlights the need for further research and alternative treatment options for CMV infection in pediatric patients. [Extracted from the article]

A 52-year-old man experienced kidney injury and lack of efficacy during treatment for a pseudomonas aeruginosa infection. The man had a history of self-inflicted burns and had been admitted to a burn center. He underwent multiple surgical interventions and experienced septic shock, acute kidney insufficiency, and various infections. The man was eventually treated with phage therapy and showed improvement, leading to his discharge from the ICU after 203 days. [Extracted from the article]

A 40-year-old woman with type-1 diabetes mellitus developed infective endocarditis (IE) secondary to Corynebacterium striatum while undergoing immunosuppressive therapy and off-label treatment for COVID-19. The woman had received a simultaneous pancreas-kidney transplantation and was taking prednisolone, tacrolimus, and everolimus. After being diagnosed with COVID-19, she received oxygen therapy, remdesivir, and off-label treatment with dexamethasone. Her condition worsened, and she developed septic acute respiratory distress syndrome. She was treated with antibiotics and underwent valve replacement surgery, eventually recovering and being discharged. The IE was attributed to the medications she was taking. [Extracted from the article]

An 18-year-old woman developed acute respiratory distress syndrome while being treated with cotrimoxazole for pyelonephritis. She also experienced lack of efficacy during treatment with meropenem, azithromycin, and hydrocortisone for pneumonia. The woman presented with symptoms such as lethargy, sore throat, dyspnea, and a nonproductive cough. She was admitted to the hospital and diagnosed with acute respiratory distress syndrome, which was suspected to be caused by cotrimoxazole. The woman required intensive care and mechanical ventilation, and eventually underwent a bilateral lung transplant. She was discharged after 28 days. Atovaquone was chosen for prophylaxis against Pneumocystis jirovecii. [Extracted from the article]

A 28-year-old man experienced lack of efficacy after using cisatracurium-besilate and heparin off-label for SARS-CoV-2 infection. He initially presented with upper respiratory symptoms and was diagnosed with the infection. Despite receiving mechanical ventilation and cisatracurium-besilate, his condition worsened, leading to acute respiratory distress syndrome (ARDS). He required extracorporeal membrane oxygenation (ECMO) and eventually underwent a double-lung transplantation, which resulted in significant improvement in oxygenation. He experienced some complications, but ultimately showed preserved pulmonary function and was discharged without complications. [Extracted from the article]

A 67-year-old man with a medical history of diabetes mellitus experienced a lack of efficacy with vancomycin, cefepime, and unspecified steroids for septic shock. The man had undergone spinal fusion surgery and developed complications including acute respiratory distress syndrome (ARDS), septic shock, acute kidney injury, and atrial fibrillation. Despite treatment with various medications, his condition worsened, and his family ultimately decided to withdraw medical care. Post-death testing revealed that the man had contracted human granulocytic anaplasmosis from a tick bite. The lack of improvement with the medications was considered a factor in his outcome. [Extracted from the article]

A case report published in Reactions Weekly describes a 32-year-old woman who exhibited lack of efficacy during treatment with Cefazolin for methicillin sensitive Staphylococcus aureus (MSSA). The woman had a history of hospitalization for bilateral lower extremity weakness and severe pneumonia with pulmonary eosinophilia. Despite adequate treatment with cefazolin, her condition worsened, and she required intubation and mechanical ventilation. She was eventually diagnosed with eosinophilic granulomatosis with polyangiitis (EGPA) and treated with prednisone. She was discharged from the hospital after a prolonged stay with oxygen therapy and a course of antibiotics. [Extracted from the article]

A 47-year-old woman experienced pulmonary edema while being treated with buprenorphine/naloxone for chronic pain. She had a history of depression, chronic pain disorder, chronic tobacco use, and had undergone biliary stent placement. Initially, she was treated for community-acquired pneumonia, but her respiratory status worsened, leading to intubation and ventilation in the ICU. She responded well to treatment with diuretics and positive end-expiratory pressure, and was eventually extubated. This is the second episode of pulmonary edema she experienced while taking buprenorphine/naloxone. [Extracted from the article]

A 45-year-old woman with a history of hypertension, psoriasis, and psoriatic arthritis was admitted to the hospital for COVID-19 pneumonia. She was treated with remdesivir, baricitinib, and dexamethasone, but her condition rapidly worsened, leading to intubation and tracheostomy placement due to acute respiratory failure. She also developed a colonic stricture as a result of COVID-19 pneumonia. This case report highlights the lack of efficacy of these medications in this particular patient. [Extracted from the article]

A 46-year-old man with a medical history of diabetes, chronic obstructive pulmonary disease (COPD), and acute respiratory failure was admitted to the hospital for pneumonia. After being treated with piperacillin/tazobactam for pneumonia caused by Pseudomonas aeruginosa, he was discharged. However, he later presented with elevated white blood cells and worsening chest radiography. He was readmitted and started on antifungal treatment with amphotericin-B due to suspicion of fungal infection. Despite receiving amphotericin-B, his respiratory status continued to decline, and he developed acute respiratory distress syndrome, indicating a lack of efficacy with the medication. The man's poorly controlled diabetes and active smoking with COPD made him more susceptible to bacterial and fungal infections. [Extracted from the article]

A 78-year-old woman developed interstitial pneumonitis while being treated with rituximab for stage 4 diffuse large B cell lymphoma. She had previously been in remission from angioimmunoblastic lymphoma and had been receiving chemotherapy with doxorubicin, vincristine, cyclophosphamide, and rituximab. The woman was admitted to the emergency department with symptoms of dyspnea, fatigue, lightheadedness, and syncope. She was diagnosed with rituximab-induced interstitial pneumonitis, which was further complicated by acute respiratory distress syndrome. Despite initial improvement, she later developed gastrointestinal bleeding and opted for hospice care, eventually passing away a month later. [Extracted from the article]

A 68-year-old woman with multiple health conditions, including hypertension, obesity, and type-2 diabetes, experienced a lack of efficacy during treatment for a methicillin-sensitive Staphylococcus aureus (MSSA) infection. She initially received amoxicillin/clavulanic acid but did not respond, and her condition worsened. She was then treated with levofloxacin, ceftriaxone, daptomycin, and cloxacillin, but her infection continued to worsen. She underwent surgery, but her condition deteriorated further, and she ultimately died from the MSSA infection. The case highlights the lack of efficacy of the various drugs used in treating the infection. [Extracted from the article]

A case series involving three patients, two men and one woman aged 31-38, was described in the article. These patients experienced a lack of efficacy when using various drugs for prophylaxis against lung transplant rejection and treatment for acute fibrinous organizing pneumonia (AFOP) or antibody-mediated rejection (AMR). Despite receiving treatment, all three patients experienced a decline in lung function and ultimately died due to AMR, respiratory failure, and AFOP. The article highlights the lack of effectiveness of these drugs in these specific cases. [Extracted from the article]

A 47-year-old man experienced staphylococcal scalded skin syndrome while being treated with methotrexate for suspected psoriatic arthritis. He also showed lack of efficacy and drug intolerance during treatment with various medications for acquired epidermolysis bullosa and psoriatic erythrodermia. Despite receiving multiple treatments, his condition worsened, and he developed systemic candidiasis, bacteremia, pneumonia, and multiple organ failure. Unfortunately, he passed away. [Extracted from the article]

This article from Reactions Weekly describes two case reports of patients who experienced a lack of efficacy while being treated with heparin for thrombosis prophylaxis. The first patient, a 45-year-old man with severe acute respiratory distress syndrome (ARDS) due to COVID-19, developed cannula-associated deep vein thrombosis (CaDVT) despite receiving heparin. The second patient, a 53-year-old man with ARDS due to COVID-19, also developed CaDVT despite heparin treatment. Both patients had complicated hospital courses and experienced various medical complications. These case reports highlight the need for further research on the efficacy of heparin in preventing thrombosis. [Extracted from the article]

A 60-year-old man with mixed connective tissue disease and interstitial lung disease-related end-stage lung disease underwent a bilateral lung transplant. After the surgery, he developed adenovirus pneumonitis and was treated with cidofovir. However, the treatment was not effective, and he ultimately died from adenovirus pneumonitis and progressive respiratory failure. [Extracted from the article]

A 95-year-old man with hypertension developed aspiration pneumonia after accidentally ingesting irrigation water and vomiting. He was initially treated with ceftriaxone, but his respiratory rate increased and he developed acute respiratory failure, indicating a lack of efficacy from the medication. The treatment was then changed to meropenem, but he experienced persistent high fever and worsening inflammatory findings, suggesting a lack of efficacy from meropenem as well. Vancomycin was added to the treatment, but the pneumonia worsened, leading to respiratory failure and the patient's death on day 12. [Extracted from the article]

A 67-year-old man developed immune aplastic anaemia while being treated with atezolizumab for non-small cell lung cancer. He later experienced a lack of efficacy when treated with immune-globulin and ciclosporin for the immune aplastic anaemia. The man had a history of ulcerative colitis, hypertension, and cured testicular seminoma. Despite receiving treatment, his bone marrow function did not recover, and he continued to require platelet and red blood cell transfusions. However, his lung cancer did not recur, and he remained in clinical remission. [Extracted from the article]

An 18-year-old pregnant woman with pre-eclampsia experienced a lack of efficacy during treatment with magnesium, labetalol, hydralazine, and nicardipine. Despite receiving these medications, her systolic blood pressure remained high and she developed multiple complications, including intracerebral hemorrhage, HELLP Syndrome, multiorgan failure, and ultimately died from cardiac arrest. This case suggests that the combination of these antihypertensive drugs was not effective in managing her condition. [Extracted from the article]

A 43-year-old man with melanoma differentiation-associated gene 5 (MDA 5) dermatomyositis exhibited lack of efficacy during treatment with multiple drugs, including cyclophosphamide, immune-globulin, mycophenolate-mofetil, tacrolimus, and tofacitinib. Despite receiving treatment, his symptoms worsened, and he experienced progressive dyspnea, cough, and respiratory failure. The patient's condition deteriorated rapidly, and he ultimately died. The article highlights the lack of efficacy of these drugs in treating MDA 5 dermatomyositis and the challenges faced in managing the patient's condition. [Extracted from the article]

A 50-year-old woman with interstitial lung disease (ILD) exhibited lack of efficacy during treatment with steroids, immune-globulin, and rituximab. She had been admitted for acute respiratory distress syndrome (ARDS) and COVID-19, requiring intubation and other interventions. Despite treatment, her ILD rapidly declined and was considered refractory. She underwent plasma-exchange and received a second dose of rituximab. Her recovery was complicated by pneumothorax, bronchopleural fistula, and critical illness weakness, but she eventually discharged to a ventilator weaning facility and then home. [Extracted from the article]

An 85-year-old man experienced respiratory depression following a fentanyl overdose. The man had a history of diabetes, hypertension, and chronic kidney disease. After undergoing surgery, he was placed on a ventilator and given fentanyl infusion. Despite attempts to decrease the dosage, the man's respiratory rate continued to decrease, indicating an opioid overdose. Naloxone was administered, but the improvement was short-lived, and end-of-life care was initiated due to the man's advanced carcinoma and multiple organ failure. [Extracted from the article]

A 30-year-old woman developed drug-induced wooden chest syndrome while being treated with fentanyl. She was hospitalized with shortness of breath and underwent intubation. She had a history of systemic lupus erythematosus and developed complications such as acute respiratory distress syndrome, acute renal failure, glomerulonephritis, and sepsis. She received treatment for aspergillosis and pneumonia, and was later diagnosed with fentanyl-induced wooden chest syndrome. Despite receiving additional treatment, she unfortunately passed away several weeks later due to this condition. [Extracted from the article]

An 18-year-old man experienced a lack of efficacy during treatment with epinephrine for haemodynamic instability after drowning in a river. Despite receiving epinephrine, his pulse rate remained low, indicating that the treatment was not effective. He was later administered epoprostenol but unfortunately developed bradycardia and asystole, leading to his death. The cause of death was determined to be differential hypoxia, bradycardia, and asystole. [Extracted from the article]

An 87-year-old man experienced a severe allergic reaction and acute respiratory failure while being treated with dyclonine for oral local laryngeal anesthesia. He also did not respond well to dexamethasone for his severe allergic reaction. The man had visited the hospital due to pharyngeal discomfort and pain, and his symptoms worsened over time. He was admitted to the ICU and received various treatments before eventually being discharged. [Extracted from the article]

A 55-year-old woman with diabetes mellitus and hypothyroidism presented to the emergency department with a cough and difficulty breathing. She was diagnosed with acute respiratory distress syndrome (ARDS) and severe pneumonia and was treated with ceftriaxone, levofloxacin, and methylprednisolone. However, further investigation revealed the presence of certain antibodies, despite the treatment. The antibiotics were discontinued, but methylprednisolone was continued, and the patient eventually recovered and was discharged on oral prednisolone. [Extracted from the article]

A 26-year-old man experienced a range of serious medical complications after overdosing on oxycodone. He was brought to the hospital unresponsive and was diagnosed with acute respiratory failure, cardiorespiratory arrest, rhabdomyolysis, respiratory acidosis, acute kidney injury, aspiration pneumonia, toxic leukoencephalopathy, Anton-Babinski syndrome (ABS), and quadriplegia. He received treatment for pneumonia and his rhabdomyolysis improved with hydration. Neurological examinations revealed severe encephalopathy and he was started on seizure prophylaxis. Brain MRI showed extensive leukoencephalopathy. After several weeks of treatment, he gradually regained visual and motor function and was eventually discharged to a rehabilitation hospital. [Extracted from the article]

A case report published in Reactions Weekly describes the medical history and treatment of a 58-year-old man with urothelial carcinoma. The patient developed diabetes mellitus while receiving pembrolizumab, insulin resistance and haemophagocytic lymphohistiocytosis (HLH) while receiving enfortumab-vedotin, and liver function test alterations while receiving pioglitazone. He also experienced severe thrombocytopenia while receiving etoposide. Despite treatment, the patient's condition worsened, and he ultimately died from HLH. This case highlights the potential toxicities associated with these medications and the importance of monitoring patients closely during treatment. [Extracted from the article]

Two case reports are presented in this article, highlighting the lack of efficacy of certain drugs in the treatment of hyperkalaemia and rhabdomyolysis. In the first case, a 4-year-old boy with influenza A infection experienced ventricular tachycardia and hyperkalaemia despite receiving bicarbonate, salbutamol, insulin, and glucose. He also did not respond to sodium chloride, albumin-human, and plasma infusions. However, his condition eventually improved after receiving continuous veno-venous hemodiafiltration and other interventions. In the second case, an 11-month-old boy with motor development delay did not respond to sodium chloride for rhabdomyolysis and required continuous veno-venous hemodiafiltration. Although he was initially discharged, he later experienced a recurrence of rhabdomyolysis and died after unsuccessful cardiopulmonary resuscitation. [Extracted from the article]

A 72-year-old man with renal cell carcinoma developed immune-mediated myositis and respiratory failure while being treated with pembrolizumab. He also experienced lack of efficacy with immune globulin and prednisone. The patient presented with abdominal pain and diarrhea, followed by vocal cord paralysis, muscle weakness, and acute respiratory failure. After receiving plasmapheresis and steroids, he showed significant improvement and was successfully weaned off the ventilator. This case highlights the potential side effects and treatment challenges associated with pembrolizumab therapy. [Extracted from the article]

A 22-year-old man developed acute infectious purpura fulminans (AIPF) while being treated with ibuprofen and diclofenac for fever and pain. The man had a history of alcoholism and presented with fever, escharotic and purpuric skin lesions on his lower limbs, and other symptoms. He was diagnosed with AIPF, Klebsiella pneumoniae, and Human Herpesvirus Type 5, among other conditions. The AIPF was considered secondary to the infections and was also attributed to the use of ibuprofen and diclofenac. The man received various treatments during his hospitalization and eventually showed improvement and was discharged. [Extracted from the article]

A 25-year-old woman experienced a lack of efficacy during her treatment with ceftriaxone and moxifloxacin for a Salmonella typhimurium infection. She was admitted to the hospital with symptoms such as weakness, diarrhea, vomiting, abdominal pain, and hypotension. Despite receiving treatment with moxifloxacin and later ceftriaxone, her condition did not improve. Additional treatments were administered, including ciprofloxacin, fluids, and symptomatic treatments, but her condition continued to worsen. Eventually, her treatment was switched to meropenem, which led to an improvement in her condition and she was discharged three weeks later. [Extracted from the article]

A 24-year-old man experienced a lack of efficacy while being treated off-label with molnupiravir for COVID-19 and artemether/lumefantrine for Plasmodium falciparum malaria. After returning from a trip abroad, he developed symptoms of COVID-19 and tested positive. Despite receiving molnupiravir therapy, his COVID symptoms worsened. He was then admitted to the hospital and diagnosed with Plasmodium falciparum malaria. Treatment with artemether/lumefantrine did not improve his condition, and he experienced various complications. Eventually, his condition improved with the use of artesunate, and he was discharged after 5 weeks. [Extracted from the article]

A 41-year-old woman with multiple medical conditions, including antiphospholipid syndrome, recurrent pulmonary embolism, and deep vein thrombosis, experienced a lack of efficacy during anticoagulant therapy with warfarin. Despite undergoing suction thrombectomy to remove multiple small chronic clots, a large saddle embolus remained. The woman was discharged on warfarin but presented again with acute respiratory failure a month later. A CT angiogram revealed that the large saddle embolism was still present, indicating a lack of efficacy to warfarin. Although advised for mechanical thrombectomy, the woman and her family declined surgery and she continued on warfarin. [Extracted from the article]

A 27-year-old man experienced lack of efficacy and liver injury while being treated for thyrotoxicosis. He presented with symptoms such as palpitations and difficulty breathing, and was found to have an elevated heart rate and blood pressure. The man's condition worsened, leading to complications such as heart failure, respiratory distress syndrome, and acute renal failure. After several weeks of treatment, his condition improved and he was able to undergo further procedures for his condition. [Extracted from the article]

A 60-year-old man with a history of arterial hypertension and overweight experienced lack of efficacy during treatment with prednisolone and nitric-oxide for acute respiratory distress syndrome. After being hospitalized for a flu-like syndrome, his condition worsened despite receiving prednisolone, leading to intubation and mechanical ventilation. He was later diagnosed with COVID-19 and diastolic dysfunction, and received off-label treatments for both conditions. Despite treatment with inhalation nitric-oxide, his severe hypoxia persisted. Eventually, he was diagnosed with bronchopneumonia and acute immuno-depression syndrome, and received appropriate treatments. With treatment, his condition improved, and he was discharged from the hospital. [Extracted from the article]

A 51-year-old man with advanced lung adenocarcinoma developed pneumonitis and colitis while being treated with pembrolizumab. He also developed drug resistance to colitis during treatment with methylprednisolone. The man exhibited lack of efficacy when treated with methylprednisolone, remdesivir, heparin, and unspecified antibiotics for COVID-19 infection. Despite receiving treatment, he died from acute respiratory distress syndrome and respiratory failure caused by COVID-19. [Extracted from the article]

A 46-year-old man with a medical history of hypertension, poorly controlled diabetes, chronic obstructive pulmonary disease, and current tobacco use presented to a rural clinic with various symptoms. He was diagnosed with Pseudomonas infection and received treatment with levofloxacin and piperacillin/tazobactam, but his condition worsened. Further investigations revealed a Blastomyces dermatitidis infection, and he was treated with itraconazole and amphotericin-B-liposomal. However, despite these treatments, his respiratory failure and acute respiratory distress syndrome (ARDS) worsened, and he ultimately passed away. The lack of efficacy of the medications used was observed in this case. [Extracted from the article]

A retrospective cohort study of six male patients aged 58-68 years with hepatocellular carcinoma was conducted to examine the lack of efficacy, hepatotoxicity, and drug intolerance associated with various drugs. Patient 1 exhibited lack of efficacy to nivolumab, while Patient 2 showed lack of efficacy to atezolizumab and bevacizumab. Patient 3 experienced lack of efficacy to nivolumab, and Patient 4 showed lack of efficacy to bevacizumab and atezolizumab. Patient 5 developed hepatotoxicity secondary to nivolumab and ipilimumab. Despite these adverse reactions, none of the patients experienced clinical evidence of graft rejection after orthotopic liver transplantation. [Extracted from the article]

In a retrospective observational study, a patient with moderate to severe COVID-19 infection was treated with multiple drugs including remdesivir, canakinumab, colchicine, and doxofylline. However, the patient exhibited a lack of efficacy and ultimately died. The patient also received off-label treatment with canakinumab, colchicine, and doxofylline. The study suggests that these drugs may not be effective for treating COVID-19. [Extracted from the article]

A 42-year-old woman with asthma and respiratory symptoms was treated for multidrug-resistant tuberculosis with amikacin, ethambutol, levofloxacin, linezolid, meropenem, and pyrazinamide. Initially, she showed improvement, but her condition worsened, indicating a lack of efficacy. She developed acute respiratory distress syndrome and required intubation. After receiving steroids for tuberculosis-induced immune reconstitution inflammatory syndrome, her ventilator settings improved. Testing confirmed multidrug-resistant tuberculosis with resistance to rifampin and isoniazid, and her final treatment regimen consisted of bedaquiline, linezolid, pretomanid, and moxifloxacin. She eventually required a tracheostomy but was successfully weaned off the ventilator. [Extracted from the article]

A 48-year-old woman with B-thalassemia received off-label treatment with cortisone for COVID-19. She had a severe COVID-19 episode in August 2021, requiring hospitalization and transfusion therapy. She also developed diffuse arthralgias and flu-like symptoms seven months later, with confirmation of SARSCov2 infection. Despite receiving cortisone, there was no improvement, leading to a lack of efficacy with cortisone. [Extracted from the article]

A 69-year-old woman developed hantavirus pulmonary syndrome (HPS) while undergoing immunosuppressive treatment with mycophenolate-mofetil and tacrolimus. She had a history of orthotopic liver transplantation, transplant failure, breast cancer, and melanoma. She presented with symptoms such as shortness of breath, headaches, body aches, fevers, and fatigue. Despite receiving antibiotics for suspected pneumonia, her condition worsened rapidly, requiring oxygen and leading to acute respiratory distress syndrome (ARDS). The woman was eventually diagnosed with HPS caused by the medications she was taking. She received treatment at a tertiary care center and eventually recovered, although she developed lung fibrosis. [Extracted from the article]

A 57-year-old man with multiple myeloma developed Legionnaire's disease and other infections. He was initially treated with meropenem, vancomycin, and doxycycline, but his condition worsened. His treatment was changed to levofloxacin, but he developed acute renal failure and metabolic acidosis. Despite receiving various treatments, including cefiderocol for multidrug-resistant infections, his condition continued to deteriorate. Ultimately, his family chose comfort care, and he passed away due to acute renal failure and acute respiratory distress syndrome. [Extracted from the article]